Syndicate content

Rare Mutations in RINT1 Tumor Suppressor Gene Associated with Early-Onset Breast Cancer and Possibly Other Cancers

An international team of scientists has identified an association between heritable, rare mutations in the RINT1 gene and increased risk of early-onset breast cancer, according to research reported today (October 24) at the American Society of Human Genetics (ASHG) 2013 Annual Meeting in Boston. The rare mutations in RINT1, a tumor suppressor gene, were detected in 3 of 49 families participating in a study that sequenced the whole exome, the protein-coding DNA, of families with multiple individuals affected by breast cancer. “Although mutations in RINT1 are rare, it is most likely that the remaining unknown breast cancer susceptibility genes will account for similar small proportions of the disease,” said Daniel J. Park, Ph.D., who presented the study at ASHG 2013 and is Senior Research Fellow in genetic epidemiology at the University of Melbourne, Australia. Only approximately 35 percent of the familial risk for breast cancer has been explained so far, according to Dr. Park and his collaborators, who added that the discovery of the RINT1 variants’ association with the disease could help members of families with multiple cases of breast cancer to identify their individual risk for developing the cancer. Dr. Park’s collaborators in the search for unidentified breast cancer susceptibility genes are scientists at the Institute Curie in Paris, the International Agency for Research on Cancer in Lyon, France, the Huntsman Cancer Institute in Salt Lake City, Utah, as well as the University of Melbourne. After pinpointing the first three mutations in RINT1 (p.Q115X, p.M378del, and p.D403Y), the international team of scientists assessed the association between the variants and breast cancer risk by conducting a population-based case-control study of 1,313 women diagnosed with early-onset (45 years of age or younger) breast cancer. Rare RINT1 variants were uncovered in 23 individuals in this group, but in only 6 women out of 1,123 who did not have breast cancer, demonstrating a significant association between RINT1 mutations and risk of early-onset breast cancer, according to the researchers. In parallel, an additional 684 women with breast cancer who are members of multiple-case breast cancer families were screened for RINT1 mutations, and six additional rare mutations were identified. The scientists reported that research identifying RINT1 as a breast cancer susceptibility gene is consistent with prior studies showing that mice that carry a RINT1 mutation spontaneously develop a variety of tumors, including breast cancer, at a combined rate of 81 percent, which is higher than the rate at which breast cancer spontaneously develops in laboratory mice that have a BRCA1 mutation. In their analysis of the families of women with RINT1 mutations, the researchers found a statistically significant 2- to 3-fold excess of cancers associated with mismatch repair defects, such as those found in patients with hereditary non-polyposis colon cancer (HNPCC). This finding indicates that RINT1 mutations may predispose to several other types of tumors, the scientists reported. In particular, the mutations were suggested to be associated with HNPCC-spectrum cancers. Previous studies have shown that RINT1 serves as a tumor suppressor essential for maintaining the function of the Golgi apparatus, which packages proteins inside the cell, and the integrity of the centrosome, which coordinates mitosis, a stage of cell division that separates two identical sets of chromosomes into newly dividing cells. Dr. Park also reported work indicating that RINT1 may interact with the RAD50 protein, which is involved in homologous recombination repair of damaged DNA. He also cited suggestive evidence reported earlier by others that RINT1 may also interact with BRCA1. This BioQuick report is based largely on an ASHG press release. The ASHG is the primary professional membership organization for nearly 8,000 human genetics specialists worldwide. The ASHG Annual Meeting is the world's largest gathering of human genetics professionals and a forum for renowned experts in the field. Approximately 6,700 genetics professionals are attending the 2013 annual meeting in Boston, which runs through Saturday, October 26. For more information about the ASHG, visit: The image shows cells stained with fluorescent antibodies to the RINT1 protein. [ASHG press release] [ASHG Annual Meeting 2013]